Updated July 8, 2022
For those unvaxed with past Covid infection, now Covid + with symptoms and seeking care, Physicians will prescribe Paxlovid that is NOT FDA approved. It is just like the vaccines, Emergency Use Authorized ONLY!
According to the UK Daily mail on June 28, 2022:
- “According to Pfizer’s own data, the drug is limited in its abilities to fight Covid-19 in a vaccinated person
- The CDC issued a warning about the potential for Covid-19 rebound symptoms after taking Paxlovid in May 2022
- The warning noted that none of the reported rebound cases saw patients suffer a severe case of Covid-19, though Fauci described his symptoms as ‘much worse’
- A UC San Diego study found that patients who were experiencing Covid rebound symptoms suffered because Paxlovid did not get to enough infected cells”.
Access the complete article here
May 31, 2022
Reuters reports on May 28, 2022, the use of emergency authorized Paxlovid spiked this week. “Some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time. More quarantine time is not a crowd-pleaser,” Dr. Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. For those people who really aren’t at risk … I would recommend that they not take it.”
They report, “More than 162,000 courses were dispensed last week – compared with an average of 33,000 a week since the drug was launched late last year, according to government data. Biden administration officials have pushed for wide use of Paxlovid, which the government purchased and provides free”.
They continue, “Paxlovid’s emergency authorization stipulates that it should be used only for newly infected people with risk factors, but doctors said many others have sought out a prescription”.
Closing with it is “estimated the rate of Paxlovid-related COVID rebounds at around 10% – higher than the 3-4% rate cited by Pfizer in its trials of the drug”.
Access the Reuters Article on Physician’s Not Recommending Paxlovid for those at low risk of infection
Who is high risk?
Mayo Clinic states, “the risk of developing dangerous symptoms of COVID-19 may be increased in people who are older. The risk may also be increased in people of any age who have other serious health problems — such as heart or lung conditions, weakened immune systems, obesity, or diabetes. This is similar to what is seen with other respiratory illnesses, such as the flu (influenza). Each of these factors can increase the risk of severe COVID-19 symptoms. But people who have several of these other health problems are at even higher risk”.
April 30, 2022
According to Reuters, “Pfizer on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus“.
Reuters continues, “the trial enrolled 3,000 adults who were household contacts exposed to an individual who was experiencing symptoms, given Paxlovid for five or 10 days or a placebo. Those who took the five-day course were found to be 32% less likely to become infected than the placebo group. That rose to 37% with 10 days of Paxlovid. However, the results were not statistically significant and thus possibly due to chance. Pfizer said safety data in the trial was consistent with previous studies”.
Access the complete reuter’s article here
December 22, 2021
Daniel Horowitz at the Blaze Media reports the FDA plans to approve Paxlovid under an emergency use authorization (EUA) the ‘first out of hospital treatment’ in the history of man’s war against Covid.
The first three Covid drugs approved under EUA were Remdesivir, Baricitinib, and Tofacitinib. All were EUA approved for inpatient use (in hospital) only, demonstrate dismal effectiveness and are replete with ‘black box warnings’ and side effects such as organ failure, blood clots, serious infections and malignancy.
Dr. Ryan Cole on the drug’s mechanism of action after infection explains, the Covid virus enters the cell, commandeers the cell forcing it to produce proteins. Protease enzymes must be present for the virus to successfully complete the destructive cycle ending in the destruction of the cell.
Paxlovid or any drug classified as a ‘Protease Inhibitor’ will inhibit or decrease the Protease enzyme interfering with the virus allowing the cell to heal. Ivermectin is the most safe, widely used, and proven protease inhibitor, in production today. Just as with Paxlovid, Ivermectin decreases the Protease enzyme but…the benefits of Ivermectin in Covid treatment are obvious and not present in Paxlovid. Additional actions of Ivermectin include anti-coagulant action and anti-inflammatory actions, both observed in Covid infections. Ivermectin was the only Protease Inhibitor out of the 13 tested to fully bind (inhibit) “the enzyme”.
Another small consideration, the Paxlovid requires combination with an HIV/AIDS drug, Ritonavir preventing the breakdown of the Paxlovid so it may inhibit or decrease the enzyme thereby interrupting the virus. Dr. Cole reports Ritonavir also has its own ‘black box warning’ and side effects include life-threatening liver, pancreas and heart issues.
Access the full Op-Ed article here
